IMR Press / EJGO / Volume 23 / Issue 3 / pii/2002159

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

Expression of NM23 and tenascin in invasive ductal carcinomas of the breast

Show Less
1 Marmara University Hospital, Pathology Department, ?stanbul (Turkey)
2 SSK Ankara Training Hospital, Di?kap?, Ankara (Turkey)
Eur. J. Gynaecol. Oncol. 2002, 23(3), 261–263;
Published: 10 June 2002
Abstract

Objective: In this series of ductal carcinoma of the breast, immunoexpression of antimetastasis gene nm23 and tenascin was exa­mined and the role in prognosis was investigated by correlation with the tumour grade and stage, and ER/PR immunoexpression. Material and Methods: In this study 27 ductal carcinomas of the breast were analysed for expression of tenascin and nm23 anti­metastasis genes by immunohistochemistry. Results: The results of our study revealed a statistically significant correlation between nm23-H1 immunoexpression and lymph node metastasis. We also found a statistically significant correlation between tenascin and nm23-H1 immunoexpression. Our results suggest that tenascin limits tumour spread. Conclusion(s): Antimetastasis gene expression can be used in predicting lymph node metastasis in ductal carcinomas of the breast.

Keywords
Tenascin
nm23 expression
Ductal carcinoma
Breast
Share
Back to top